Belgian healthcare is under huge pressure to balance the costs associated with new innovations, but continual price cuts for generics are threatening the system’s sustainability and…
In Conversation
Hong Kong can continue to leverage our clear advantage as the international bridge between the globe and China
By investing so much in the Belgian ecosystem, we can be an important player on several fronts, leveraging the voice of the innovative industry
We need a strong independent regulator with a one-country, two-way system framework that takes China into consideration
The only critical success factor in moving forward and getting innovative products reimbursed is for pharmaceutical companies to be seen as a real partner; a real…
Patients are the true experts as the only actors that know what living with a condition is like and the impact of a treatment on how…
In Belgium we are generally good at treating conditions but not so good at preventing them, and this is also the case with diabetes
Everybody needs to know how important phase I studies are in clinical research. Without them, there would be no new drugs or vaccines
Access is vital. Having the chance to find innovative treatments and then not making them available to patients would be a dramatic and ethically unacceptable situation
For life sciences to flourish and for successful start-ups to be born you need a complete infrastructure ecosystem covering everything from laboratories to manufacturing sites, MNCs…
While we recognize the importance of innovation for the pharmaceutical landscape and the need to address unmet medical needs, we advocate for a fair and equal…
We are very proud to say that 30 percent of the eye drops sold in Belgium are Théa products
